SAG
RYTM icon

SageView Advisory Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

SageView Advisory Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30
Closed -$3.21K – 2065
2025
Q4 		$3.21K Buy
+30
New +$3.18K ﹤0.01% 2092

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

SageView Advisory Group's RYTM Position: Q1 2026 in Review

SageView Advisory Group sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 30 shares — an estimated $3.21K sold.

SageView Advisory Group first reported a position in RYTM in Q4 2025 and held it in 1 quarter. The position peaked at $3.21K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • SageView Advisory Group reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 30 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $3.21K.
  • SageView Advisory Group first reported a position in Rhythm Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Rhythm Pharmaceuticals position peaked at $3.21K in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.